Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
Recruiting · NCT07516886 · Observational (researchers observe without assigning treatment) · Lead sponsor: Lithuanian University of Health Sciences
View the official record on ClinicalTrials.gov →Interventions studied
Radical Prostatectomy
What this trial is about
This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer. No investigational interventions will be performed. All diagnostic procedures, follow-up assessments, and treatments will be conducted in accordance with standard clinical practice and established prostate cancer management guidelines. Participation in the study will not influence treatment decisions.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patient is an adult biological male.
- Patient has morphologically confirmed and untreated prostate cancer.
- Patient who will be treated with open, laparoscopic or robot-assisted laparoscopic radical prostatectomy.
- Patient is informed about this observational study and has signed the informed consent form.
Exclusion criteria
- Patient has radiologically of morphologically confirmed prostate cancer metastases before the operation.
- Patient received neoadjuvant prostate cancer treatment.
- Patient is set to receive adjuvant treatment.
- Patient has any contraindications for the operation.
Where it is running
1 location listed.
- Lithuanian University of Health Sciences Hospital Kaunas Clinics, Department of Urology - Kaunas, Kauno, Lithuania